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Editorial
Multidisciplinary pulmonary embolism care: an exciting time
to join the team
Pulmonary Circulation 2019; 9(1) 1–2
DOI: 10.1177/2045894019829071
Pulmonary embolism (PE) remains a major cause of mor-
bidity and mortality in hospitalized patients and is a top
cause of cardiovascular death behind myocardial infarction
and stroke, two disease states which have seen the formal-
ization of team-based care that can be rapidly activated and
deployed for expeditious and expert treatment.1 Only
recently in this decade, and in conjunction with the advances
of new therapeutic options for PE including catheter-
directed thrombolysis and thromboaspiration, have we
seen the emergence of the PE Response Team (PERT) in
an attempt to improve care for this deadly disease. First
described by Massachusetts General Hospital and in oper-
ation since 2013, the PERT is modeled off of the deployment
of Rapid Response Teams meant to bring specialized
resources to hospitalized patients in an effort to rescue
and prevent further deterioration. The team can be rapidly
activated and expert care from multiple stakeholder special-
ties can be planned and coordinated with the patient and
primary physician.2–4 Modeled after this team approach,
PERTs have rapidly spread in hospitals across America
and, in 2015, the PERT Consortium was created to help
focus ongoing mission goals, including the creation of regis-
try data on patients treated under this care model. At the
time of publication, the PERT Consortium comprises over
60 founding and institutional member hospitals.5
In this issue of Pulmonary Circulation, Jacob Schultz
and colleagues describe the first-year experience of the ori-
ginal eight large tertiary care centers participating in the
PERT Registry. In this report, the authors describe charac-
teristics of PERT activations, with a variety in frequency
of activations between hospitals and hospital wards.
Characteristics of PE are described in terms of presence of
right heart strain by biomarker, radiographic or echocardio-
graphic evidence and stratified by risk classification
according to European Society of Cardiology guidelines.
A variety of treatment options were employed including
anticoagulation alone in the majority as well as advanced
therapy including systemic or catheter-directed thromboly-
sis, catheter-directed thromboaspiration, surgical embolec-
tomy, Extracorporeal Membrane Oxygenation, or inferior
vena cava filter placement. Finally, event rates for 30-day
mortality, major bleeding, and recurrent venous thrombo-
embolism (VTE) are reported and stratified by risk
category.6
This report brings the first multicenter analysis of PERT
registry data and highlights some of the phenomena that we
in practice in high-volume centers know to be true.
However, it leaves some unanswered questions that, hope-
fully, pooled consortium data will rapidly clarify.
The PERT composition is not a one-size-fits-all team
and, just as diverse as the patient populations described,
must be tailored to a hospital’s capabilities and its popula-
tion’s needs. Our PERT has isolated physician champions in
core subspecialties of Pulmonary/Critical Care Medicine,
Pulmonary Hypertension, Advanced Heart Failure
Cardiology, Cardiac Surgery, Interventional Cardiology,
and Interventional Radiology. Emergency Physicians and
Internist experts with an interest in anticoagulation contrib-
ute to our team with additional support from Vascular
Surgery and Hematology. Notable in this study is a
marked difference in location of activation of the teams
between hospitals, suggesting the ongoing need for indivi-
dualized team structure and underscoring the importance in
careful scrutiny of quality improvement measures that are
integral to each team’s success.
The question on every practitioner’s mind at this point is
addressed but unfortunately not answered by the limited
amount of data presented: outcomes for advanced therapy
compared to anticoagulation alone. As reported previously
in the initial single-center experience, pooled major bleeding
was similar between the groups treated with anticoagulation
alone and patients treated with catheter-based techniques,
adding important safety data to the evidence base. However,
the low event rate in both studies suggests under-powering
of the data that will likely require a large registry to
answer.2,6 This study also points out that in the PERT
population, recurrent VTE events occur equally across risk
groups, but appeared to trend higher in groups treated with
catheter-based strategies and systemic thrombolysis for
unclear reasons.6
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Perhaps the presence of a PERT in a hospital selects out a
different population of patients than previously studied. The
pooled mortality rates are markedly varied between the
study sites and, with additional data, may be correlated
potentially with outside hospital transport to the study hos-
pital specifically for PERT service or activation from the
intensive care unit, postoperative or oncology wards, sug-
gesting a higher prevalence of co-morbid conditions contri-
buting to overall outcome, but at present the population size
did not allow for analysis of co-morbid factors. Our own
PERT experience parallels this suggestion; with the growth
of our program, a wider case mix of patients is following
and special challenges in inter-hospital transport and
increasing acuity have brought a selected and ultimately
sicker population to our care.
The reported 30-day mortality for each risk group was
higher than previously reported before the PERT era.7 Most
striking, mortality in the low-risk group was 11%, com-
pared to 0.5% in the previous prediction model.6,7 The
authors introduce the concept of a low-risk patient with
high-risk features. These patients may have initially come
to the attention of the multidisciplinary team for complex
management of co-morbidities. Additionally, the present
ESC classification does not take into account common
features including saddle PE, clot in transit, syncope, or
predicted difficult anticoagulation in co-morbid or post-
operative patients—conditions which may bring more risk
than suggested by PE severity indices and initial clinical
stratification data. Low-risk co-morbid patients may have
features that complicate accurate stratification. These
patients often come to the attention of the PERT based
on primary provider concern for these features and their
implication on outcomes. The rapid assessment and decision
support provided by the multidisciplinary team for low-risk
patients with high-risk features is, in our experience, valu-
able to the bedside clinician and, given the mortality data in
this patient population, appears to be an important area for
need of ongoing research that may lead to altogether refined
stratification definitions.
The authors’ reporting on the number of PERT activa-
tions is thought-provoking to any clinician interested in
starting a PERT program. The average reported dosing of
calls is eight per month per 1000 beds, but variable among
the institutions.6 Depending on resources, each call involves
physicians of multiple specialties during non-traditional
hours in teleconference; time commitment for clinical and
administrative duty is immense. This care coordination and
increased on-call burden often goes largely uncompensated,
with only procedural and clinic downstream revenue for
some of the team providers. The asymmetric returns are
often not appreciated at the point of team creation and
require significant time and capital investment, but when
realized, are immense. Our team receives positive feedback
on the collaboration our cross-functional group can provide
for decision support on complex patients and we feel pride
in our high-quality multidisciplinary care. Formalized
PERT clinic follow-up has allowed for the earlier detection
and treatment of chronic thromboembolic pulmonary
hypertension (CTEPH), a devastating but potentially cur-
able sequela, when found early. Participation in the PERT
Consortium has brought us together with like-minded phys-
icians across the country interesting in advancing care.
The data provided by Schultz and colleagues is an excit-
ing beginning to a new era of PE research. Coordinated care
for complicated patients done in high-quality centers may
finally pool together, by way of the PERT registry, the
powered data necessary to answer the ongoing questions
in our field. Are our current risk stratification guidelines
accurate in predicting outcome? Who benefits from
advanced therapy and can we impact morbidity and mortal-
ity? Do our expanded care options or post-PE follow-up
help us earlier identify long-term sequelae of acute PE
including the Post-PE syndrome and CTEPH? The PERT
consortium members are well primed to carry out multicen-
ter prospective trials to additionally help guide future thera-
pies. Amid these questions, a point of clarity exists in the
rapid growth of PERT driven therapy for this complicated
and heterogeneous disease state, and a wealth of informa-
tion will be obtained to advance the care of our patients.
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